Veterans Affairs Medical Center - White River Junction

Summary

Veterans Affairs Medical Center - White River Junction is a medical facility located in White River Junction, Vermont. This center is recognized for care of Lung Cancer, Post-Traumatic Stress Disorder, Leukemia, Colorectal Cancer, Non-Small Cell Lung Cancer and other specialties. Veterans Affairs Medical Center - White River Junction is involved with conducting 113 clinical trials across 154 conditions. There are 10 research doctors associated with this hospital, such as Britt H. Olmsted, Natalie Riblet, MD MPH, Florian R Schroeck, MD, MS, and Bradley V Watts, MD, MPH.

Top PIs

Clinical Trials running at Veterans Affairs Medical Center - White River Junction

Lung Cancer

Non-Small Cell Lung Cancer

Suicide Prevention

Post-Traumatic Stress Disorder

Opiate Dependence

Opioid Use Disorder

Suicidal Ideation

Suicide Attempt

Self-Harm

Suicide

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3

Cemiplimab

for Non-Small Cell Lung Cancer

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.

Recruiting

1 award

Phase 2 & 3

19 criteria